Cytovia licenses CAR NK tech to NCI

By The Science Advisory Board staff writers

January 13, 2021 -- Cytovia Therapeutics has signed a licensing agreement with the National Cancer Institute (NCI), part of the National Institutes of Health, to apply its gene-edited induced pluripotent stem cell (iPSC)-derived technology to develop glypican-3 (GPC3) chimeric antigen receptor (CAR) natural killer (NK) cell therapeutics.

Mitchell Ho, PhD, director of the Antibody Engineering Program and deputy chief of the Laboratory of Molecular Biology at the NCI Center for Cancer Research has developed novel antibodies and CARs binding to GPC3 on liver cancer cells. GPC3 is an antigen involved in cell proliferation and is highly expressed in hepatocellular carcinoma tumor cells as well as other solid tumors.

Cytovia has also signed a cooperative research and development agreement with NCI where the company will collaborate with the Ho lab to develop and evaluate gene-edited iPSC-derived CAR NK cells. The company plans to file an initial new drug application for its GPC3 CAR NK cells in the first half of 2022.

$105M raised for Senti Bio to develop CAR-NK therapies
Leaps by Bayer, the investment arm of Bayer AG, and Senti Biosciences (Senti Bio) have announced a $105 million series B financing round to develop...
Glycostem licenses Ghent tech to advance NK cell therapies
Glycostem Therapeutics and Ghent University have signed a license agreement for natural killer (NK) cell production technology, with the goal of producing...
Avectas, ONK to develop cancer cell therapy
Avectas has exclusively licensed a chimeric antigen receptor-directed natural killer cell therapy from ONK Therapeutics for the treatment of B-cell malignancies...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter